Adicet Bio To Report Clinical Data From Phase 1 Study Evaluating Prulacabtagene Leucel As Potential Treatment For Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis On September 28

Adicet Bio, Inc. (NASDAQ: ACET) will report clinical data from its Phase 1 study on prulacabtagene leucel (prula-cel) as a potential treatment for systemic lupus erythematosus, including cases with or without lupus nephritis, on September 28, 2026. The company will also host a webcast presentation at 8:00am ET to discuss the results following the announcement.